Key Findings:  This case report of a 64-year-old woman with lichen simplex chronicus and squamous cell carcinoma who applied topical 20% cannabidiol. Her lesions were successfully treated within less than 4 weeks, as well as complete regression of several biopsy-confirmed squamous cell carcinomas. The hypothesized mechanism involves the CB1 and CB2 receptors of the endocannabinoid system and their anti-inflammatory properties.
Type of Study:  Meta-analysis
Study Sample Size:  1
Study Result:  Positive
Study Location(s):  United States
Year of Pub:  2022
Cannabinoids Studied:  Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabinol (CBN), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), JWH-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), N-Arachidonoyl Dopamine (NADA), Virodhamine (O-AEA), Endocannabinoid (unspecified), Pharma THC, Pharma THC:CBD, Cannabidivarin (CBDV), Palmitoylethanolamide (PEA)
Phytocannabinoid Source:  Cannabis Flower derived
Terpenes Studied:  ß-Caryophyllene
Receptors Studied:  CB1, CB2, GPCR